![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0014.png)
Biomedical Research
|
Volume 29
Page 52
Note:
allied
academies
CARDIOLOGY AND CARDIOVASCULAR MEDICINE
STEM CELLS AND REGENERATIVE MEDICINE
&
International Conference on
International Conference on
J u n e 1 8 - 1 9 , 2 0 1 8 | O s a k a , J a p a n
Joint Event on
CLINICAL APPLICATION OF AUTOLOGOUS WHOLE BONE
MARROW STEM CELL TRANSPLANTATION FOR CRITICAL
LIMB ISCHEMIA WITH BUERGER’S DISEASE
Dong-ik Kim
Samsung Medical Centre, South Korea
K
oreaOur goal was to evaluate early results of the clinical application of autologous whole bonemarrow stemcell transplantation
(AWBMSCT) for critical limb ischemia (CLI) in patients with Buerger’s disease. We retrospectively analyzed the data of 58
limbs of 37 patients (mean age, 43.0 years; range, 28-63 years; male, 91.9%) with Buerger’s disease with CLI who were treated
with AWBMSCT. We analyzed Rutherford category, pain score, pain-free walking time (PFWT), total walking time (TWT), ankle
brachial pressure index (ABPI), and toe brachial pressure index (TBPI), and investigated wound healing and occurrence of
unplanned amputations. The mean follow-up duration was 11.9±7.2 months (range, 0.9-23.9 months) and 100%, 72.4%, and
74.1% of patients were available to follow-up 1, 3 and 6 months after AWBMST, respectively. At 6 months, patients demonstrated
significant improvements in Rutherford category (P<0.0001), pain score (P<0.0001), PFWT (P<0.0001) and TBPI (P<0.0001).
ABPI was increased compared to baseline, but the difference was not significant. A total of 76.5% ischemic wounds achieved
complete or improved healing. AWBMSCT is a safe and effective alternative or adjunctive treatment modality to achieve clinical
improvement in patients with CLI.
dikim@skku.eduBiomed Res 2018, Volume 29 | DOI: 10.4066/biomedicalresearch-C2-006